These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33131251)

  • 1. Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura.
    Graça NAG; Ercig B; Carolina Velásquez Pereira L; Kangro K; Kaijen P; Nicolaes GAF; Veyradier A; Coppo P; Vanhoorelbeke K; Männik A; Voorberg J
    Haematologica; 2020 Nov; 105(11):2619-2630. PubMed ID: 33131251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An autoantibody epitope comprising residues R660, Y661, and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF.
    Pos W; Crawley JT; Fijnheer R; Voorberg J; Lane DA; Luken BM
    Blood; 2010 Feb; 115(8):1640-9. PubMed ID: 20032502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-glycan-mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP.
    Ercig B; Graça NAG; Kangro K; Arfman T; Wichapong K; Hrdinová J; Kaijen P; van Alphen FPJ; van den Biggelaar M; Vanhoorelbeke K; Veyradier A; Coppo P; Reutelingsperger C; Nicolaes GAF; Männik A; Voorberg J
    Blood; 2021 May; 137(19):2694-2698. PubMed ID: 33544829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenic hotspots in the spacer domain of ADAMTS13 in immune-mediated thrombotic thrombocytopenic purpura.
    Velásquez Pereira LC; Roose E; Graça NAG; Sinkovits G; Kangro K; Joly BS; Tellier E; Kaplanski G; Falter T; Von Auer C; Rossmann H; Feys HB; Reti M; Prohászka Z; Lämmle B; Voorberg J; Coppo P; Veyradier A; De Meyer SF; Männik A; Vanhoorelbeke K
    J Thromb Haemost; 2021 Feb; 19(2):478-488. PubMed ID: 33171004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
    Jian C; Xiao J; Gong L; Skipwith CG; Jin SY; Kwaan HC; Zheng XL
    Blood; 2012 Apr; 119(16):3836-43. PubMed ID: 22289888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
    Roose E; Vidarsson G; Kangro K; Verhagen OJHM; Mancini I; Desender L; Pareyn I; Vandeputte N; Vandenbulcke A; Vendramin C; Schelpe AS; Voorberg J; Azerad MA; Gilardin L; Scully M; Dierickx D; Deckmyn H; De Meyer SF; Peyvandi F; Vanhoorelbeke K
    Thromb Haemost; 2018 Oct; 118(10):1729-1742. PubMed ID: 30235483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.
    Zheng XL; Wu HM; Shang D; Falls E; Skipwith CG; Cataland SR; Bennett CL; Kwaan HC
    Haematologica; 2010 Sep; 95(9):1555-62. PubMed ID: 20378566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.
    Mancini I; Valsecchi C; Lotta LA; Deforche L; Pontiggia S; Bajetta M; Palla R; Vanhoorelbeke K; Peyvandi F
    Thromb Haemost; 2014 Aug; 112(2):297-303. PubMed ID: 24740645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain.
    Pos W; Sorvillo N; Fijnheer R; Feys HB; Kaijen PH; Vidarsson G; Voorberg J
    Haematologica; 2011 Nov; 96(11):1670-7. PubMed ID: 21712537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope analysis of autoantibodies to ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
    Yamaguchi Y; Moriki T; Igari A; Nakagawa T; Wada H; Matsumoto M; Fujimura Y; Murata M
    Thromb Res; 2011 Aug; 128(2):169-73. PubMed ID: 21496883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome.
    Casina VC; Hu W; Mao JH; Lu RN; Hanby HA; Pickens B; Kan ZY; Lim WK; Mayne L; Ostertag EM; Kacir S; Siegel DL; Englander SW; Zheng XL
    Proc Natl Acad Sci U S A; 2015 Aug; 112(31):9620-5. PubMed ID: 26203127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
    Thomas MR; de Groot R; Scully MA; Crawley JT
    EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADAMTS-13 conformation influences autoimmune recognition in immune thrombotic thrombocytopenic purpura.
    Underwood MI; Thomas MR; Scully MA; Crawley JTB
    J Thromb Haemost; 2024 Apr; 22(4):1069-1079. PubMed ID: 38160729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of inhibition of human monoclonal antibodies in immune thrombotic thrombocytopenic purpura.
    Halkidis K; Meng C; Liu S; Mayne L; Siegel DL; Zheng XL
    Blood; 2023 Jun; 141(24):2993-3005. PubMed ID: 37023370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura.
    Postmus T; Graça NAG; Ferreira de Santana J; Ercig B; Langerhorst P; Luken B; Joly BS; Vanhoorelbeke K; Veyradier A; Coppo P; Voorberg J
    J Thromb Haemost; 2023 Dec; 21(12):3402-3413. PubMed ID: 37633643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple B-cell clones producing antibodies directed to the spacer and disintegrin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in a patient with acquired thrombotic thrombocytopenic purpura.
    Luken BM; Kaijen PH; Turenhout EA; Kremer Hovinga JA; van Mourik JA; Fijnheer R; Voorberg J
    J Thromb Haemost; 2006 Nov; 4(11):2355-64. PubMed ID: 16898953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP.
    De Waele L; Curie A; Kangro K; Tellier E; Kaplanski G; Männik A; Tersteeg C; Joly BS; Coppo P; Veyradier A; De Meyer SF; Roose E; Vanhoorelbeke K
    Blood Adv; 2021 Nov; 5(21):4480-4484. PubMed ID: 34559219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [anti-ADAMTS13 autoantibodies in patients with thrombotic thrombocytopenic purpura].
    Matsumoto M
    Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(2):95-103. PubMed ID: 23629429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura.
    Grillberger R; Casina VC; Turecek PL; Zheng XL; Rottensteiner H; Scheiflinger F
    Haematologica; 2014 Apr; 99(4):e58-60. PubMed ID: 24532042
    [No Abstract]   [Full Text] [Related]  

  • 20. Naturally Occurring Anti-Idiotypic Antibodies Portray a Largely Private Repertoire in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
    Heeb SR; Schaller M; Kremer Hovinga JA
    J Immunol; 2022 Jun; 208(11):2497-2507. PubMed ID: 35589126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.